Cargando…
One-year Results of Aflibercept Treatment for Polypoidal Choroidal Vasculopathy with Good Visual Acuity
PURPOSE: To evaluate the one-year efficacy of intravitreal aflibercept injection in polypoidal choroidal vasculopathy (PCV) with best-corrected visual acuity (BCVA) of 20 / 40 or better. METHODS: This was a multicenter retrospective study. The medical records of patients diagnosed with treatment-naï...
Autores principales: | Kwon, Ji Min, Pak, Kang Yeun, Lee, Jae Jung, Sagong, Min, Kim, Hyun Woong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Ophthalmological Society
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904418/ https://www.ncbi.nlm.nih.gov/pubmed/33307629 http://dx.doi.org/10.3341/kjo.2020.0096 |
Ejemplares similares
-
Choroidal structure as a biomarker for visual acuity in intravitreal aflibercept therapy for polypoidal choroidal vasculopathy
por: Asano, Shotaro, et al.
Publicado: (2018) -
Intravitreal aflibercept for active polypoidal choroidal vasculopathy without active polyps
por: Lee, Sang Eun, et al.
Publicado: (2019) -
One-year outcomes of fixed-dosing Aflibercept therapy for pre treated and naive polypoidal choroidal vasculopathy patient
por: Choo, Hun Gu, et al.
Publicado: (2021) -
Polypoidal choroidal vasculopathy as a complication of choroidal osteoma: A case report
por: Kim, Doyeon, et al.
Publicado: (2020) -
Comparison of the 2-Year Results of Photodynamic Therapy with Aflibercept and Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy
por: Miyakubo, Tomoko, et al.
Publicado: (2023)